Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Next Previous
Drug Profile

Bepotastine besilate - Mitsubishi Tanabe Pharma Corporation

Alternative Names: Bepotastine; Bepreve; Betotastine; Betotastine besilate; Talion; TAU-284

Latest Information Update: 15 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ube Industries
  • Developer Dong-A ST; ISTA Pharmaceuticals; Mitsubishi Tanabe Pharma Corporation; Ube Industries
  • Class Antiallergics; Antiasthmatics; Antihistamines; Antipruritics; Butyric acids; Chlorobenzenes; Eye disorder therapies; Piperidines; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Perennial allergic rhinitis; Pruritus; Urticaria
  • No development reported Seasonal allergic rhinitis

Most Recent Events

  • 23 Apr 2019 Phase-I clinical trials in Perennial allergic rhinitis (In volunteers) in South Korea (PO) (NCT03932435)
  • 01 Nov 2018 Preregistration for Allergic rhinitis in Thailand (PO) (Mitsubishi Tanabe Pharma pipeline, February 2019)
  • 01 Nov 2018 Preregistration for Urticaria in Thailand (PO) (Mitsubishi Tanabe Pharma pipeline, February 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top